JUST IN
Meta partners with Salesforce, to offer WhatsApp biz messaging services
Air India Express incurs net loss for the first time in seven years
M&M to acquire Swaraj Engines' 17.41% stake from Kirloskar Industries
NDTV promoters move Supreme Court against SAT order
Byju's focusing on profitable growth, $2 bn revenue in sight: CEO to staff
Growth forecast in US market set to drive gains for Cipla stock
Can Fin Homes stock under pressure second day in row, sheds 4% on BSE
ONDC and UPI together will reorder India's supply chain: Nandan Nilekani
McLeod Russel India lenders likely to discuss Carbon Resources proposal
OYO working on 'green tag' for sustainable hotels on its platform: CEO
You are here: Home » Companies » News
Can Fin Homes stock under pressure second day in row, sheds 4% on BSE
Business Standard

Growth forecast in US market set to drive gains for Cipla stock

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

Topics
Cipla | Nifty Pharma | Pharma stocks

Ram Prasad Sahu 

Cipla, Cipla logo, Cipla headquarters
Cipla is the only generic player in the market and had launched the drug seven months earlier in February

The stock of pharma major Cipla was the biggest gainer in the Nifty Pharma and Healthcare indices, jumping about 5.5 per cent in trade on Tuesday. The Healthcare index also saw the largest increase among sectoral indices with a rise of about 3 per cent.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.
OR
Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Cipla

First Published: Tue, September 20 2022. 21:21 IST

`
RECOMMENDED FOR YOU
.